BURLINGTON, ON, Oct. 4, 2012 /PRNewswire/ - EKO International Inc. (EKNL-Pinksheets) announces that NeuroVasc Clinical Inc.,( NCI) is commencing an awareness campaign notifying health care practitioners that clinics providing treatment for Diabetic Peripheral Neuropathy will soon be available for their patients. Diabetic neuropathies, affect over 50% of diabetics. If left untreated, diabetic neuropathies trigger foot ulcers that may require amputation, may cause disabling chronic pain and may increase the risk of falling to the elderly. The annual cost of diabetic neuropathies has been estimated at $14 billion in the United States.
The treatment of Diabetic Peripheral Neuropathy is the main intended use for the proprietary FREMS device now being distributed in North America by NCI.
NCI also distributes the NC-Stat DPN check device which is a point of care nerve conduction measurement tool essential in the early detection of peripheral neuropathy. Patients who score poorly on the nerve conduction test are prime candidates for FREMS treatments and this is very valuable information for Physicians, Pharmacists , Podiatrists and Certified Diabetic Educators .
EKO, NeuroVasc Medical Inc. and NCI will continue to support the Canadian and American Diabetes Associations' call for the annual testing of all diabetics for peripheral neuropathy and will work to educate the community about the role FREMs can play in treating neuropathy and in preventing leg ulcers and their devastating complications.
Of interest is the following quote:
"Is the testing service now available to the general public and where can it be found?
The product is relatively new to the market having been introduced late last year. Through the end of June, we've placed 590 devices with physicians and health care professionals in North America, including WalMart-Canada pharmacies where the test is offered as a part of a comprehensive foot examination at 100 of their stores.
Also, the large San-Antonio, Texas based managed care organization, WellMed, has adopted the technology and plans to test its patient population numbering about 100,000. "-News Medical- http://www.news-medical.net/news/20120806/Medical-devices-for-diabetic-peripheral-neuropathy-an-interview-with-Dr-Shai-Gozani-CEO-of-NeuroMetrix.aspx
This press release contains forward-looking statements that reflect the Company's current expectation regarding future events. Actual events could differ materially and substantially from those projected herein and depend on a number of factors. Certain statements in this release, and other written or oral statements made by EKO International ("The Company") are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. You should not place undue reliance on forward-looking statements since they involve known and unknown risks, uncertainties and other factors, which are, in some cases, beyond the Company's control and which could, and likely will, materially affect actual results, levels of activity, performance or achievements. The Company assumes no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future. Important factors that could cause actual results to differ materially from the company's expectations include, but are not limited to, those factors that are disclosed under the heading "Risk Factors" and elsewhere in documents filed by the company from time to time with the United States Securities and Exchange Commission and other regulatory authorities.
SOURCE EKO INTERNATIONAL CORP.